


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable ~~form~~ salt thereof, wherein:

A and B are independently CR_{2a} or N;

D, E and F are independently CH or N;

X and Y are independently CR_x or N;

R_x is independently chosen at each occurrence from hydrogen, C₁-C₆alkyl, amino, and mono- and di-(C₁-C₆alkyl)amino;

Z is O or NR_z; wherein R_z is hydrogen, C₁-C₆alkyl or taken together with R_{1a} to form a fused heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C₁-C₆alkyl, C₁-C₆alkoxy and C₁-C₆haloalkyl;

R_{1a} is:

(i) chosen from halogen, cyano, -COOH, C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;

(ii) taken together with R_z to form a fused heterocyclic ring; or

(iii) taken together with R₄ to form a fused carbocyclic ring;


R₁ represents from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, -COOH, C₁-C₆alkyl, C₁-C₆alkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, mono- and di-(C₁-C₆alkyl)amino,

C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;

R₂ and each R_{2a} are independently chosen from hydrogen, hydroxy, amino, halogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;

R₃ is selected from:

- (i) halogen, hydroxy and haloC₁-C₆alkyl;
- (ii) phenylC₀-C₄alkyl and pyridylC₀-C₄alkyl; and
- (iii) groups of the formula:



wherein

L is a single covalent bond or C₁-C₆alkylene;

R₅ and R₆ are:

- (a) independently chosen from hydrogen, C₁-C₈alkyl, C₁-C₈alkenyl, C₂-C₈alkanoyl, (C₃-C₈cycloalkyl)C₀-C₄alkyl, (3- to 7-membered heterocycloalkyl)C₀-C₄alkyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl, such that if L is a single bond, then R₅ and R₆ are not phenyl or pyridyl; or
- (b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R₇ is C₁-C₈alkyl, (C₃-C₈cycloalkyl)C₀-C₄alkyl, C₁-C₈alkenyl, C₂-C₈alkanoyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C₁-C₆alkyl, C₃-C₈cycloalkyl, C₂-C₆alkyl ether, C₁-C₆alkoxy, C₂-C₆alkanoyl, C₁-C₆haloalkyl, mono- and di-(C₁-C₆alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C₁-C₄alkyl, C₁-C₄alkoxy and C₁-C₄haloalkyl; and

R₄ is hydrogen, C₁-C₆alkyl or taken together with R_{1a} to form a fused carbocyclic ring.

2-5. (Cancelled)..

6. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~ salt thereof according to claim 5, wherein R_3 is a group of the formula $-N(R_5)(R_6)$, wherein R_5 and R_6 are:

- (a) independently chosen from hydrogen, C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, C_1 - C_6 alkenyl, benzyl and $-\text{CH}_2$ -pyridyl; or
- (b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

wherein each of which alkyl, cycloalkyl, alkenyl, benzyl, pyridyl and heterocycloalkyl is substituted with from 0 to 3 substituents independently chosen from halogen, amino, cyano, hydroxy, C_1 - C_4 alkyl, C_2 - C_4 alkyl ether, C_1 - C_4 alkoxy, C_1 - C_4 haloalkyl and mono- and di- $(C_1$ - C_4 alkyl)amino.

7. (Currently Amended) A compound or pharmaceutically acceptable salt ~~form~~-thereof according to claim 6, wherein R_3 is mono- or di- $(C_1$ - C_6 alkyl)amino.

8. (Currently Amended) A compound or pharmaceutically acceptable salt ~~form~~-thereof according to claim 6, wherein R_3 is benzylamino or $-\text{NH}-\text{CH}_2$ -pyridyl, each of which is substituted with from 0 to 2 substituents independently chosen from halogen, amino, hydroxy, cyano, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, and C_1 - C_4 haloalkyl.

9. (Currently Amended) A compound or pharmaceutically acceptable salt ~~form~~-thereof according to claim 6, wherein R_3 is pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl or azepanyl, each of which is substituted with from 0 to 3 substituents independently chosen from halogen, amino, hydroxy, cyano, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, and C_1 - C_4 haloalkyl.


10. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~salt thereof according to claim 1, wherein R_3 is a group of the formula $-O-R_7$ wherein R_7 is hydrogen, C_1 - C_6 alkyl, phenyl C_0 - C_6 alkyl or pyridyl C_0 - C_6 alkyl, wherein each alkyl, phenyl and pyridyl is substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and C_1 - C_4 alkoxy.

11-12. (Cancelled).

13. (Currently Amended) A compound or pharmaceutically acceptable salt ~~form~~ thereof according to claim 1, wherein R_2 and each R_{2a} are independently chosen from hydrogen, amino, halogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 alkylsulfonyl and mono- and di- $(C_1$ - C_4 alkyl)sulfonamido, and wherein at least one of R_2 or R_{2a} is not hydrogen.


14-18. (Cancelled).

19. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~salt thereof according to claim 1, wherein the compound has the formula:




20. (Cancelled).

21. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~salt thereof according to claim 1, wherein the compound has the formula:




22-23. (Cancelled).

24. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~salt thereof according to claim 1, wherein the compound has the formula:



25-27. (Cancelled).

28. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

A is CR_{2a} or N;

D, E, F and U are independently CH or N;

X and Y are independently CR_x or N;

R_x is independently chosen at each occurrence from hydrogen, C_1 - C_6 alkyl, amino, cyano, and mono- and di- $(C_1$ - C_6 alkyl)amino;

Z is O or NR_z ; wherein R_z is hydrogen, C_1 - C_6 alkyl or taken together with R_{1a} to form a fused heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_1 - C_6 haloalkyl;

V is O or NR_v ; wherein R_v is hydrogen, C_1 - C_6 alkyl or taken together with an R_8 to form a fused heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_1 - C_6 haloalkyl;

R_{1a} is:

(i) chosen from halogen, cyano, $-COOH$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxy, mono- and di- $(C_1$ - C_6 alkyl)amino, C_1 - C_6 alkylsulfonyl, mono- and di- $(C_1$ - C_6 alkyl)sulfonamido, and mono- and di- $(C_1$ - C_6 alkyl)aminocarbonyl; or

(ii) taken together with R_z to form a fused heterocyclic ring; or

(iii) taken together with R_4 to form a fused carbocyclic ring;

R_1 represents from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, $-COOH$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_6 alkyl ether, C_2 - C_6 alkanoyl, C_3 - C_6 alkanone, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxy, mono- and di- $(C_1$ - C_6 alkyl)amino, C_1 - C_6 alkylsulfonyl, mono- and di- $(C_1$ - C_6 alkyl)sulfonamido, and mono- and di- $(C_1$ - C_6 alkyl)aminocarbonyl;


R_8 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, amino, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_6 alkyl ether, C_2 - C_6 alkanoyl, C_3 - C_6 alkanone, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxy, mono- and di- $(C_1$ - C_6 alkyl)amino, C_1 - C_6 alkylsulfonyl, mono- and di- $(C_1$ - C_6 alkyl)sulfonamido, and mono- and di- $(C_1$ - C_6 alkyl)aminocarbonyl; or R_8 is taken together with R_v to form a fused heterocyclic ring;

R_2 and each R_{2a} are independently chosen from hydrogen, hydroxy, amino, cyano, halogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkyl ether, C_2 - C_6 alkanoyl, C_3 - C_6 alkanone, mono- and di- $(C_1$ - C_6 alkyl)amino, C_1 - C_6 alkylsulfonyl, mono- and di- $(C_1$ - C_6 alkyl)sulfonamido, and mono- and di- $(C_1$ - C_6 alkyl)aminocarbonyl; and

R_4 is hydrogen, C_1 - C_6 alkyl or taken together with R_{1a} to form a fused carbocyclic ring.

29-42. (Cancelled).

43. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

A, D, E and F are independently CH or N;

X and Y are independently CR_x or N;

R_x is independently chosen at each occurrence from hydrogen, C₁-C₆alkyl, amino, and mono- and di-(C₁-C₆alkyl)amino;

R_{1a} is:

(i) chosen from halogen, cyano, amino, -COOH, C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl; or

(ii) taken together with R₄ to form a fused carbocyclic ring;


R₁ represents from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, -COOH, C₁-C₆alkyl, C₁-C₆alkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;

R₂ is chosen from hydroxy, amino, cyano, halogen, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;

R_{2a} represents from 0 to 2 substituents independently chosen from hydroxy, amino, cyano, halogen, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;

R₃ is selected from:

- (i) halogen, hydroxy and haloC₁-C₆alkyl;
- (ii) phenylC₀-C₄alkyl and pyridylC₀-C₄alkyl; and
- (iii) groups of the formula:



wherein

L is a single covalent bond or C₁-C₆alkylene;

R₅ and R₆ are:

- (a) independently chosen from hydrogen, C₁-C₈alkyl, C₁-C₈alkenyl, C₂-C₈alkanoyl, (C₃-C₈cycloalkyl)C₀-C₄alkyl, (3- to 7-membered heterocycloalkyl)C₀-C₄alkyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl, such that if L is a single bond, then R₅ and R₆ are not phenyl or pyridyl; or
- (b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R₇ is C₁-C₈alkyl, C₃-C₈cycloalkyl(C₀-C₄alkyl), C₁-C₈alkenyl, C₂-C₈alkanoyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C₁-C₆alkyl, C₃-C₈cycloalkyl, C₂-C₆alkyl ether, C₁-C₆alkoxy, C₂-C₆alkanoyl, C₁-C₆haloalkyl, mono- and di-(C₁-C₆alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C₁-C₄alkyl, C₁-C₄alkoxy and C₁-C₄haloalkyl; and

R₄ is hydrogen, C₁-C₆alkyl or taken together with R_{1a} to form a fused carbocyclic ring.


44-57. (Cancelled).

58. (Currently Amended) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable ~~form~~salt thereof according to ~~any one of~~ |

~~claims 1, 28 or 43~~claim 1 in combination with a physiologically acceptable carrier or excipient.

59. (Original) A pharmaceutical composition according to claim 58 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

60. (Currently Amended) A method for reducing calcium conductance of a cellular capsaicin receptor, comprising contacting a cell expressing a capsaicin receptor with at least one compound having the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

Ar₁ is phenyl or a 6-membered aromatic heterocycle, each of which is substituted with from 0 to 4 substituents independently chosen from R₁;

Ar₂ is phenyl, pyridyl or pyrimidyl, each of which is substituted with from 0 to 4 substituents independently chosen from R₂;

X and Y are independently CR_x or N; wherein R_x is independently chosen at each occurrence from hydrogen, C₁-C₆alkyl, amino, mono- and di-(C₁-C₆alkyl)amino, and cyano;

Z is O or NR_z; wherein R_z is hydrogen, C₁-C₆alkyl or taken together with a R₁ moiety to form a fused, partially saturated heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C₁-C₆alkyl, C₁-C₆alkoxy and C₁-C₆haloalkyl;

Each R₁ is independently:


- (i) chosen from halogen, hydroxy, amino, cyano, -COOH, C₁-C₆alkyl, C₁-C₆alkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;
- (ii) taken together with R_z to form a fused heterocyclic ring; or
- (iii) taken together with R₄ to form a fused carbocyclic ring;

Each R₂ is independently:

- (i) chosen from hydrogen, hydroxy, amino, cyano, halogen, -COOH, aminocarbonyl, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, C₁-C₆haloalkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl; or
- (ii) taken together with an adjacent R₂ to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen and C₁-C₆alkyl;

R₃ is selected from:

- (i) hydrogen, hydroxy and halogen;
- (ii) C₁-C₆alkyl, C₃-C₈cycloalkyl, phenylC₀-C₄alkyl and pyridylC₀-C₄alkyl; and
- (iii) groups of the formula



wherein

L is a single covalent bond or C₁-C₆alkylene;

R₅ and R₆ are:

- (a) independently chosen from hydrogen, C₁-C₈alkyl, C₁-C₈alkenyl, C₂-C₈alkanoyl, (C₃-C₈cycloalkyl)C₀-C₄alkyl, (3- to 7-membered heterocycloalkyl)C₀-C₄alkyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl; or
- (b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and


R₇ is C₁-C₈alkyl, C₃-C₈cycloalkyl(C₀-C₄alkyl), C₁-C₈alkenyl, C₂-C₈alkanoyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is optionally substituted, preferably with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C₁-C₆alkyl, C₃-C₈cycloalkyl, C₂-C₆alkyl ether, C₁-C₆alkoxy, C₂-C₆alkanoyl, C₁-C₆haloalkyl, mono- and di-(C₁-C₆alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently

chosen from halogen, hydroxy, amino, cyano, C₁-C₄alkyl, C₁-C₄alkoxy and C₁-C₄haloalkyl; and
 each R₄ is hydrogen, C₁-C₆alkyl or taken together with a R₁ to form a fused carbocyclic ring;
 and thereby reducing calcium conductance of the capsaicin receptor.

61-81. (Cancelled).

82. (Currently Amended) A method for treating a condition responsive to capsaicin receptor modulation in a patient, comprising administering to the patient a capsaicin receptor modulatory amount of a compound having the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

Ar₁ is phenyl or a 6-membered aromatic heterocycle, each of which is substituted with from 0 to 4 substituents independently chosen from R₁;

Ar₂ is phenyl, pyridyl or pyrimidyl, each of which is substituted with from 0 to 4 substituents independently chosen from R₂;

X and Y are independently CR_x or N; wherein R_x is independently chosen at each occurrence from hydrogen, C₁-C₆alkyl, amino, mono- and di-(C₁-C₆alkyl)amino, and cyano;

Z is O or NR_z; wherein R_z is hydrogen, C₁-C₆alkyl or taken together with a R₁ moiety to form a fused, partially saturated heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C₁-C₆alkyl, C₁-C₆alkoxy and C₁-C₆haloalkyl;

Each R₁ is independently:


- (i) chosen from halogen, hydroxy, amino, cyano, -COOH, C₁-C₆alkyl, C₁-C₆alkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;
- (ii) taken together with R_z to form a fused heterocyclic ring; or
- (iii) taken together with R₄ to form a fused carbocyclic ring;

Each R₂ is independently:

- (i) chosen from hydrogen, hydroxy, amino, cyano, halogen, -COOH, aminocarbonyl, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, C₁-C₆haloalkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl; or
- (ii) taken together with an adjacent R₂ to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen and C₁-C₆alkyl;

R₃ is selected from:

- (i) hydrogen, hydroxy and halogen;
- (ii) C₁-C₆alkyl, C₃-C₈cycloalkyl, phenylC₀-C₄alkyl and pyridylC₀-C₄alkyl; and
- (iii) groups of the formula



wherein

L is a single covalent bond or C₁-C₆alkylene;

R₅ and R₆ are:

- (a) independently chosen from hydrogen, C₁-C₈alkyl, C₁-C₈alkenyl, C₂-C₈alkanoyl, (C₃-C₈cycloalkyl)C₀-C₄alkyl, (3- to 7-membered heterocycloalkyl)C₀-C₄alkyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl; or
- (b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R₇ is C₁-C₈alkyl, C₃-C₈cycloalkyl(C₀-C₄alkyl), C₁-C₈alkenyl, C₂-C₈alkanoyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is optionally substituted, preferably with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C₁-C₆alkyl, C₃-C₈cycloalkyl, C₂-C₆alkyl ether, C₁-C₆alkoxy, C₂-C₆alkanoyl, C₁-C₆haloalkyl, mono- and di-(C₁-C₆alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently

chosen from halogen, hydroxy, amino, cyano, C₁-C₄alkyl, C₁-C₄alkoxy and C₁-C₄haloalkyl; and
each R₄ is hydrogen, C₁-C₆alkyl or taken together with a R₁ to form a fused carbocyclic ring;
and thereby alleviating the condition in the patient.


83. (Original) A method according to claim 82, wherein the patient is suffering from (i) exposure to capsaicin, (ii) burn or irritation due to exposure to heat, (iii) burns or irritation due to exposure to light, (iv) burn, bronchoconstriction or irritation due to exposure to tear gas, air pollutants or pepper spray, or (v) burn or irritation due to exposure to acid.

84. (Original) A method according to claim 82, wherein the condition is asthma or chronic obstructive pulmonary disease.

85. (Original) A method according to claim 82, wherein the compound is a compound according to claim 1.

86-87. (Cancelled).

88. (Currently Amended) A method for treating pain in a patient, comprising administering to a patient suffering from pain a capsaicin receptor modulatory amount of at least one compound having the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

Ar₁ is phenyl or a 6-membered aromatic heterocycle, each of which is substituted with from 0 to 4 substituents independently chosen from R₁;

Ar₂ is phenyl, pyridyl or pyrimidyl, each of which is substituted with from 0 to 4 substituents independently chosen from R₂;

X and Y are independently CR_x or N; wherein R_x is independently chosen at each occurrence from hydrogen, C₁-C₆alkyl, amino, mono- and di-(C₁-C₆alkyl)amino, and cyano;

Z is O or NR_z; wherein R_z is hydrogen, C₁-C₆alkyl or taken together with a R₁ moiety to form a fused, partially saturated heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C₁-C₆alkyl, C₁-C₆alkoxy and C₁-C₆haloalkyl;

Each R₁ is independently:


- (i) chosen from halogen, hydroxy, amino, cyano, -COOH, C₁-C₆alkyl, C₁-C₆alkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;
- (ii) taken together with R_z to form a fused heterocyclic ring; or
- (iii) taken together with R₄ to form a fused carbocyclic ring;

Each R₂ is independently:

- (i) chosen from hydrogen, hydroxy, amino, cyano, halogen, -COOH, aminocarbonyl, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, C₁-C₆haloalkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl; or
- (ii) taken together with an adjacent R₂ to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen and C₁-C₆alkyl;

R₃ is selected from:

- (i) hydrogen, hydroxy and halogen;
- (ii) C₁-C₆alkyl, C₃-C₈cycloalkyl, phenylC₀-C₄alkyl and pyridylC₀-C₄alkyl; and
- (iii) groups of the formula



wherein

L is a single covalent bond or C₁-C₆alkylene;

R₅ and R₆ are:

- (a) independently chosen from hydrogen, C₁-C₈alkyl, C₁-C₈alkenyl, C₂-C₈alkanoyl, (C₃-C₈cycloalkyl)C₀-C₄alkyl, (3- to 7-membered

heterocycloalkyl)C₀-C₄alkyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl; or

(b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R₇ is C₁-C₈alkyl, C₃-C₈cycloalkyl(C₀-C₄alkyl), C₁-C₈alkenyl, C₂-C₈alkanoyl, phenylC₀-C₆alkyl, pyridylC₀-C₆alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is optionally substituted, preferably with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C₁-C₆alkyl, C₃-C₈cycloalkyl, C₂-C₆alkyl ether, C₁-C₆alkoxy, C₂-C₆alkanoyl, C₁-C₆haloalkyl, mono- and di-(C₁-C₆alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C₁-C₄alkyl, C₁-C₄alkoxy and C₁-C₄haloalkyl; and

each R₄ is hydrogen, C₁-C₆alkyl or taken together with a R₁ to form a fused carbocyclic ring;

and thereby alleviating pain in the patient.


89-91. (Cancelled).

92. (Original) A method according to claim 88, wherein the patient is suffering from neuropathic pain.

93. (Original) A method according to claim 88, wherein the pain is associated with a condition selected from: postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, bilateral peripheral neuropathy, causalgia, neuritis, neuronitis, neuralgia, AIDS-related neuropathy, MS-related neuropathy, spinal cord injury-related pain, surgery-related pain, musculoskeletal pain, back pain, headache, migraine, angina, labor, hemorrhoids, dyspepsia, Charcot's pains, intestinal gas, menstruation, cancer, venom exposure, irritable bowel syndrome, inflammatory bowel disease and trauma.

94-99. (Cancelled).

100. (Currently Amended) A method for treating urinary incontinence or overactive bladder in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound having the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

Ar₁ is phenyl or a 6-membered aromatic heterocycle, each of which is substituted with from 0 to 4 substituents independently chosen from R₁;

Ar₂ is phenyl, pyridyl or pyrimidyl, each of which is substituted with from 0 to 4 substituents independently chosen from R₂;

X and Y are independently CR_x or N; wherein R_x is independently chosen at each occurrence from hydrogen, C₁-C₆alkyl, amino, mono- and di-(C₁-C₆alkyl)amino, and cyano;

Z is O or NR_z; wherein R_z is hydrogen, C₁-C₆alkyl or taken together with a R₁ moiety to form a fused, partially saturated heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C₁-C₆alkyl, C₁-C₆alkoxy and C₁-C₆haloalkyl;

Each R₁ is independently:


- (i) chosen from halogen, hydroxy, amino, cyano, -COOH, C₁-C₆alkyl, C₁-C₆alkoxy, C₂-C₆alkyl ether, C₂-C₆alkanoyl, C₃-C₆alkanone, C₁-C₆haloalkyl, C₁-C₆haloalkoxy, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆alkylsulfonyl, mono- and di-(C₁-C₆alkyl)sulfonamido, and mono- and di-(C₁-C₆alkyl)aminocarbonyl;
- (ii) taken together with R_z to form a fused heterocyclic ring; or
- (iii) taken together with R₄ to form a fused carbocyclic ring;

Each R_2 is independently:

- (i) chosen from hydrogen, hydroxy, amino, cyano, halogen, $-\text{COOH}$, aminocarbonyl, $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_1\text{-C}_6\text{haloalkyl}$, $\text{C}_1\text{-C}_6\text{alkoxy}$, $\text{C}_1\text{-C}_6\text{haloalkoxy}$, $\text{C}_2\text{-C}_6\text{alkyl ether}$, $\text{C}_2\text{-C}_6\text{alkanoyl}$, $\text{C}_3\text{-C}_6\text{alkanone}$, mono- and di- $(\text{C}_1\text{-C}_6\text{alkyl})\text{amino}$, $\text{C}_1\text{-C}_6\text{alkylsulfonyl}$, mono- and di- $(\text{C}_1\text{-C}_6\text{alkyl})\text{sulfonamido}$, and mono- and di- $(\text{C}_1\text{-C}_6\text{alkyl})\text{aminocarbonyl}$; or
- (ii) taken together with an adjacent R_2 to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen and $\text{C}_1\text{-C}_6\text{alkyl}$;

R_3 is selected from:

- (i) hydrogen, hydroxy and halogen;
- (ii) $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_3\text{-C}_8\text{cycloalkyl}$, $\text{phenylC}_0\text{-C}_4\text{alkyl}$ and $\text{pyridylC}_0\text{-C}_4\text{alkyl}$; and
- (iii) groups of the formula



wherein

L is a single covalent bond or $\text{C}_1\text{-C}_6\text{alkylene}$;

R_5 and R_6 are:

- (a) independently chosen from hydrogen, $\text{C}_1\text{-C}_8\text{alkyl}$, $\text{C}_1\text{-C}_8\text{alkenyl}$, $\text{C}_2\text{-C}_8\text{alkanoyl}$, $(\text{C}_3\text{-C}_8\text{cycloalkyl})\text{C}_0\text{-C}_4\text{alkyl}$, (3- to 7-membered heterocycloalkyl) $\text{C}_0\text{-C}_4\text{alkyl}$, $\text{phenylC}_0\text{-C}_6\text{alkyl}$, $\text{pyridylC}_0\text{-C}_6\text{alkyl}$ and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl; or
- (b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R_7 is $\text{C}_1\text{-C}_8\text{alkyl}$, $\text{C}_3\text{-C}_8\text{cycloalkyl}(\text{C}_0\text{-C}_4\text{alkyl})$, $\text{C}_1\text{-C}_8\text{alkenyl}$, $\text{C}_2\text{-C}_8\text{alkanoyl}$, $\text{phenylC}_0\text{-C}_6\text{alkyl}$, $\text{pyridylC}_0\text{-C}_6\text{alkyl}$ or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is optionally substituted, preferably with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_3\text{-C}_8\text{cycloalkyl}$, $\text{C}_2\text{-C}_6\text{alkyl ether}$, $\text{C}_1\text{-C}_6\text{alkoxy}$, $\text{C}_2\text{-C}_6\text{alkanoyl}$, $\text{C}_1\text{-C}_6\text{haloalkyl}$, mono- and di- $(\text{C}_1\text{-C}_6\text{alkyl})\text{amino}$, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently

chosen from halogen, hydroxy, amino, cyano, C₁-C₄alkyl, C₁-C₄alkoxy and C₁-C₄haloalkyl; and
each R₄ is hydrogen, C₁-C₆alkyl or taken together with a R₁ to form a fused carbocyclic ring;
and thereby alleviating urinary incontinence or overactive bladder in the patient.

101-106. (Cancelled).

107. (Currently Amended) A packaged pharmaceutical preparation, comprising:

- (a) a pharmaceutical composition according to claim 58 in a container; and
- (b) instructions for using the composition to treat pain, cough, hiccup, itch, urinary incontinence, overactive bladder, or obesity.

108-112. (Cancelled).

113. (Currently Amended) A compound or pharmaceutically acceptable salt thereof selected from the group consisting of (4-tert-Butyl-phenyl)-[4-(4-methyl-piperazin-1-yl)-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-amine, (4-tert-Butyl-phenyl)-[4-chloro-6-(2-chloro-benzyloxy)-[1,3,5]triazin-2-yl]-amine;

(4-tert-Butyl-phenyl)-[4-chloro-6-(2-methoxy-benzyloxy)-[1,3,5]triazin-2-yl]-amine,

(4-tert-Butyl-phenyl)-[4-chloro-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-amine,

(4-tert-Butyl-phenyl)-[4-chloro-6-(3,4-dihydro-1H-isoquinolin-2-yl)-[1,3,5]triazin-2-yl]-amine,

(4-tert-Butyl-phenyl)-[4-chloro-6-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-[1,3,5]triazin-2-yl]-amine,

(4-tert-Butyl-phenyl)-[4-chloro-6-(6,7-dimethoxy-3-methyl-3,4-dihydro-1H-isoquinolin-2-yl)-[1,3,5]triazin-2-yl]-amine,

(4-tert-Butyl-phenyl)-[6-(2-trifluoromethyl-benzyloxy)-pyrimidin-4-yl]-amine,
[4-(2-Chloro-phenyl)-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4-(2-Trifluoromethyl-benzyloxy)-6-(2-trifluoromethyl-phenyl)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4,6-Bis-(2-chloro-benzyloxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,
[4,6-Bis-(2-fluoro-benzyloxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,
[4,6-Bis-(2-methoxy-benzyloxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,
[4,6-Bis-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-
amine,
[4,6-Bis-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-
phenyl)-amine,
[4,6-Bis-(3-chloro-pyridin-2-ylmethoxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-
phenyl)-amine,
[4,6-Bis-(pyridin-2-ylmethoxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,
[4-Chloro-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-
phenyl)-amine,
[4-Cyclopentyloxy-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-
trifluoromethyl-phenyl)-amine,
[4-Ethoxy-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-
trifluoromethyl-phenyl)-amine,
[4-Morpholin-4-yl-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-
trifluoromethyl-phenyl)-amine,
[4-Phenyl-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-
phenyl)-amine,
[4-Pyridin-3-yl-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-
trifluoromethyl-phenyl)-amine,
2-Methyl-4-[4-(2-trifluoromethyl-benzyloxy)-6-(4-trifluoromethyl-phenylamino)-
[1,3,5]triazin-2-ylamino]-butan-2-ol,
4-(2-Trifluoromethyl-benzyloxy)-6-(4-trifluoromethyl-phenylamino)-
[1,3,5]triazin-2-ol,
6-Methyl-N-(2-trifluoromethyl-benzyl)-N'-(4-trifluoromethyl-phenyl)-
[1,3,5]triazine-2,4-diamine,
N-(2-Methoxy-ethyl)-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-
phenyl)-[1,3,5]triazine-2,4-diamine,
N-(2-Morpholin-4-yl-ethyl)-6-(2-trifluoromethyl-benzyloxy)-N'-(4-
trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,
N-(3-Methyl-butyl)-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-
phenyl)-[1,3,5]triazine-2,4-diamine,

N-(4-tert-Butyl-phenyl)-6-(2-chloro-benzyloxy)-[1,3,5]triazine-2,4-diamine,
N-(4-tert-Butyl-phenyl)-6-(2-fluoro-benzyloxy)-[1,3,5]triazine-2,4-diamine,
N-(4-tert-Butyl-phenyl)-6-(2-methoxy-benzyloxy)-[1,3,5]triazine-2,4-diamine,
N-(4-tert-Butyl-phenyl)-6-chloro-N'-(2-chloro-benzyl)-[1,3,5]triazine-2,4-
diamine,
N-(4-tert-Butyl-phenyl)-6-chloro-N'-(2-fluoro-benzyl)-[1,3,5]triazine-2,4-
diamine,
N-(4-tert-Butyl-phenyl)-6-chloro-N'-(2-methoxy-benzyl)-[1,3,5]triazine-2,4-
diamine,
N-(4-tert-Butyl-phenyl)-6-chloro-N'-(2-trifluoromethyl-benzyl)-[1,3,5]triazine-
2,4-diamine,
N-(4-tert-Butyl-phenyl)-N'-(2-chloro-benzyl)-[1,3,5]triazine-2,4,6-triamine,
N-(4-tert-Butyl-phenyl)-N'-(2-chloro-benzyl)-6-ethoxy-[1,3,5]triazine-2,4-
diamine,
N-(4-tert-Butyl-phenyl)-N'-(2-chloro-benzyl)-6-methoxy-[1,3,5]triazine-2,4-
diamine,
N-(4-tert-Butyl-phenyl)-N'-(2-chloro-benzyl)-6-methyl-[1,3,5]triazine-2,4-
diamine,
N-(4-tert-Butyl-phenyl)-N'-(2-chloro-benzyl)-N''-methyl-[1,3,5]triazine-2,4,6-
triamine,
N-(4-tert-Butyl-phenyl)-N'-(2-chloro-benzyl)-pyrimidine-4,6-diamine,
N-(4-tert-Butyl-phenyl)-N'-(2-fluoro-benzyl)-[1,3,5]triazine-2,4,6-triamine,
N-(4-tert-Butyl-phenyl)-N'-(2-fluoro-benzyl)-pyrimidine-4,6-diamine,
N-(4-tert-Butyl-phenyl)-N'-(2-methoxy-benzyl)-[1,3,5]triazine-2,4-diamine,
N-(4-tert-Butyl-phenyl)-N'-(2-methoxy-benzyl)-[1,3,5]triazine-2,4,6-triamine,
N-(4-tert-Butyl-phenyl)-N'-(2-methoxy-benzyl)-pyrimidine-4,6-diamine,
N-(4-tert-Butyl-phenyl)-N'-(2-trifluoromethyl-benzyl)-[1,3,5]triazine-2,4,6-
triamine,
N-(4-tert-Butyl-phenyl)-N'-(2-trifluoromethyl-benzyl)-pyrimidine-4,6-diamine,
N-(4-tert-Butyl-phenyl)-N'-(3-fluoro-benzyl)-pyrimidine-4,6-diamine,
N-(4-tert-Butyl-phenyl)-N'-(3-methoxy-benzyl)-pyrimidine-4,6-diamine,
N-(4-tert-Butyl-phenyl)-N'-(4-chloro-benzyl)-pyrimidine-4,6-diamine,
N-(4-tert-Butyl-phenyl)-N'-(4-methoxy-benzyl)-pyrimidine-4,6-diamine,

N-(4-tert-Butyl-phenyl)-N',N''-bis-(2-chloro-benzyl)-[1,3,5]triazine-2,4,6-triamine,
N-(4-tert-Butyl-phenyl)-N',N''-bis-(2-methoxy-benzyl)-[1,3,5]triazine-2,4,6-triamine,
N-(4-tert-Butyl-phenyl)-N'-pyridin-2-ylmethyl-pyrimidine-4,6-diamine,
N-(4-tert-Butyl-phenyl)-N'-pyridin-3-ylmethyl-pyrimidine-4,6-diamine,
N-(4-tert-Butyl-phenyl)-N'-pyridin-4-ylmethyl-pyrimidine-4,6-diamine,
N,N-Diethyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,
N4-(4-tert-Butyl-phenyl)-6-(2-trifluoromethyl-benzyloxy)-pyrimidine-2,4-diamine,
N-Benzyl-N'-(4-tert-butyl-phenyl)-pyrimidine-4,6-diamine,
N-Butyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,
N-Cyclobutyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,
N-Cyclohexyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,
N-Cyclopentyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,
N-Isobutyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,
N-Isopropyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine, and
N-tert-Butyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine, or a pharmaceutically acceptable ~~forms~~ salt thereof.

114-180. (Cancelled).

181. (New) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 28 in combination with a physiologically acceptable carrier or excipient.

182. (New) A pharmaceutical composition according to claim 181 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

183. (New) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 43 in combination with a physiologically acceptable carrier or excipient.

184. (New) A pharmaceutical composition according to claim 183 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.